HemoShear Therapeutics
Latest round
- Series A
Last raised
- Feb 2021
Total raised
- $43M
Investors
- 3
About HemoShear Therapeutics
Based in the US, HemoShear Therapeutics, Inc.HemoShear Therapeutics, Inc. specializes in creating advanced solutions for hematology and vascular health. Founded in 2008 in Charlottesville, US, by Brian Wamhoff, the company has engaged in several strategic initiatives over the years.HemoShear Therapeutics, Inc. specializes in innovative products and services aimed at advancing healthcare solutions, specifically in the realm of hematology and vascular health. The company’s core offerings focus on proprietary technologies designed to improve the understanding and treatment of blood flow-related conditions. These products are engineered for use by healthcare professionals and researchers, facilitating more accurate diagnostics and tailored treatment options for patients suffering from various blood and vascular disorders. The end users include hospitals, research institutions, and specialized clinics across North America and Europe, where these technologies are employed to enhance patient outcomes. By addressing critical issues in the treatment of blood flow and blood-related diseases, HemoShear Therapeutics, Inc.HemoShear Therapeutics, Inc. operates on a revenue model that includes direct sales to healthcare providers and partnerships with research institutions. The company generates income through the sale of its flagship products, which are utilized in clinical settings for diagnostic and therapeutic purposes. Transactions typically involve healthcare organizations purchasing products through a B2B framework, where pricing structures are aligned with the specialized nature of the offerings. Moreover, the company may engage in collaborative agreements with other entities to further enhance its market reach and product development.HemoShear Therapeutics, Inc. aims to expand its product lineup by introducing new technologies and solutions focused on hematology and vascular health in the near future. The company is also looking to penetrate new markets, particularly in Europe and Asia, by 2025.5 mn will support these initiatives, facilitating the development of new products and enhancing market expansion efforts.
Who invested in HemoShear Therapeutics
3 investors across 1 round
See all investors in HemoShear Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 10, 2021
Amount
$43M
Investors
Questions about HemoShear Therapeutics
Who invested in HemoShear Therapeutics?
HemoShear Therapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has HemoShear Therapeutics raised?
HemoShear Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did HemoShear Therapeutics last raise money?
HemoShear Therapeutics's most recent round on record is a Series A, in Feb 2021.
What does HemoShear Therapeutics do?
Based in the US, HemoShear Therapeutics, Inc.
Where is HemoShear Therapeutics headquartered?
HemoShear Therapeutics is headquartered in Charlottesville, US.
Which VCs invest in companies like HemoShear Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at HemoShear Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like HemoShear Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.